MEDICINAL APPLICATIONS OF CINNAMOMUM VERUM IN METABOLIC DISEASES: CURRENT PERSPECTIVES

Metabolic diseases, including diabetes mellitus, obesity, and dyslipidemia, have evolved into complex, multifactorial disorders driven by sedentary lifestyles, nutritional imbalance, and chronic inflammation, posing a significant global healthcare challenge. Conventional pharmacological interventions, although effective, are frequently limited by adverse effects, poor patient compliance, and inability to address multiple metabolic targets simultaneously. This has accelerated the search for multi-functional, plant-based therapeutics with integrative mechanisms of action. In this context, Cinnamomum verum (true cinnamon) has gained considerable attention as a metabolic modulator with broad-spectrum pharmacological potential. Rich in bioactive compounds such as cinnamaldehyde, eugenol, and polyphenols, Cinnamomum verum exerts pleiotropic effects on key metabolic pathways. It enhances insulin receptor signaling, promotes glucose transporter (GLUT4) translocation, and inhibits intestinal carbohydrate-digesting enzymes, thereby improving glycemic control. Simultaneously, it regulates lipid metabolism by activating AMP-activated protein kinase (AMPK), reducing adipogenesis, and improving lipid profiles. Its potent antioxidant and anti-inflammatory properties further contribute to restoring metabolic homeostasis by attenuating oxidative stress and modulating pro-inflammatory cytokines. Emerging evidence from in vitro, in vivo, and preliminary clinical studies supports its role as a systems-level therapeutic agent capable of targeting interconnected metabolic dysfunctions. However, translational challenges persist, including variability in phytochemical composition, lack of standardized formulations, and insufficient large-scale clinical validation. Future research integrating advanced delivery systems, molecular targeting, and precision phytotherapy approaches may unlock the full therapeutic potential of Cinnamomum verum, positioning it as a promising adjunct or alternative in the management of metabolic diseases.